Potential Alzheimer’s Vaccine Undergoing Pre-Clinical Trial Tests

Potential Alzheimer’s Vaccine Undergoing Pre-Clinical Trial Tests
Scientists have developed a novel form of vaccine targeting the two main proteins triggering Alzheimer's disease, amyloid-beta and tau protein. Researchers and physicians have seen an increase in Alzheimer's disease, with more than 7.5 million new cases diagnosed worldwide per year. There is an urgent but still unmet need for a vaccine and effective treatment for dementia, one of the most detrimental features of Alzheimer's disease. Researchers at Flinders University in Australia, collaborating with colleagues at the Institute of Molecular Medicine (IMM) and the University of California at Irvine (UCI), have designed a successful vaccine formulation that targets the abnormal beta-amyloid and tau proteins that signal Alzheimer's disease. The study, “Alzheimer's disease AdvaxCpG- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules, was published in the journal Scientific Reports. "If we are successful in preclinical trials, in three to five years, we could be well on the way to one of the most important developments in recent medical history," Professor Nikolai Petrovsky at Flinders University School of Medicine, and director of the South Australian vaccine research company Vaxine Pty, said in a press release. "Along with our rapidly aging populations, we now know that the explosion in type 2 diabetes in the West is likely to further dramatically fuel the p
Subscribe or to access all post and page content.